Bausch Health Companies: Pay

Bausch Health Companies paid its 4 named executives $29.3M in total in FY2025 (Dec). CEO Thomas J. Appio was paid $16.9M of that.

PayNo stock prices for these years
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Thomas J. AppioChief Executive Officer
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Jean-Jacques CharhonExecutive Vice President, Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)Not disclosed
2 years
Seana CarsonExecutive Vice President, General Counsel
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
FY2022 (Dec)Not disclosed
4 years
Aimee J. LenarExecutive Vice President, US Pharma
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

No CEO pay of the disclosed peers is on file for FY2025 (Dec).

  1. 1Bausch Health Companies
  2. 2BioMarin Pharmaceutical Inc. [BMRN]Not disclosed
  3. 3Biogen Inc. [BIIB]Not disclosed
  4. 4Elanco Animal Health Incorporated [ELAN]Not disclosed
  5. 5Hologic, Inc. [HOLX]Not disclosed
  6. 6Incyte Corporation [INCY]Not disclosed
  7. 7Jazz Pharmaceuticals plc [JAZZ]Not disclosed
  8. 8Organon & Co. [OGN]Not disclosed
  9. 9Perrigo Company plc [PRGO]Not disclosed
  10. 10Steris plc [STE]Not disclosed
  11. 11Teva Pharmaceutical Industries Limited [TEVA]Not disclosed
  12. 12United Therapeutics Corporation [UTHR]Not disclosed
  13. 13Viatris Inc. [VTRS]Not disclosed
  14. 14Zimmer Biomet Holdings Inc. [ZBH]Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.